Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials

BACKGROUND: Certolizumab pegol, an Fc‐free, PEGylated, anti‐tumour necrosis factor (TNF) biologic, has demonstrated favourable results in three ongoing, phase 3, randomized, double‐blinded, placebo‐controlled trials in adults with psoriasis. OBJECTIVE: Data were pooled from the ongoing trials to inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Blauvelt, A., Reich, K., Lebwohl, M., Burge, D., Arendt, C., Peterson, L., Drew, J., Rolleri, R., Gottlieb, A.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646900/
https://www.ncbi.nlm.nih.gov/pubmed/30242918
http://dx.doi.org/10.1111/jdv.15258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646900/
https://www.ncbi.nlm.nih.gov/pubmed/30242918
http://dx.doi.org/10.1111/jdv.15258

Ejemplares similares